{"id":85867,"date":"2021-05-07T17:05:08","date_gmt":"2021-05-07T15:05:08","guid":{"rendered":"http:\/\/www.reunion68.se\/?p=85867"},"modified":"2021-05-07T07:15:29","modified_gmt":"2021-05-07T05:15:29","slug":"15-05-63","status":"publish","type":"post","link":"https:\/\/www.reunion68.se\/?p=85867","title":{"rendered":"Two Pfizer Covid vaccine doses give over 95% protection, shows Israel study"},"content":{"rendered":"
\"\"<\/a>Two Pfizer Covid vaccine doses give over 95% protection, shows Israel study
\n<\/a><\/strong><\/span><\/h5>\n

Sarah Boseley<\/strong><\/span><\/p>\n

\n

First research of its kind shows power of vaccines to stem pandemic, cutting hospitalisation, death and infection rates<\/strong><\/span><\/h4>\n

A couple walk past a coronavirus graphic in a vaccination centre in Jerusalem, Israel. Photograph: Debbie Hill\/UPI\/REX\/Shutterstock<\/em><\/span><\/p>\n

Two doses of the Pfizer\/BioNTech vaccine have proved more than 95% effective against infection, hospitalisation and death from Covid-19 in\u00a0Israel<\/a>,<\/strong> <\/span>the country with the highest proportion of its population vaccinated in the world, research has found.<\/span><\/p>\n

One shot of the vaccine was partially effective, offering 58% protection against infection, 76% against hospitalisation, and 77% against death. The authors of the observational study\u00a0in the Lancet medical journal\u00a0<\/a><\/strong><\/span>say this shows the importance of having the second shot.<\/span><\/p>\n

Their study demonstrates the power of vaccines to end the toll of coronavirus, they say. \u201cThese findings suggest that high vaccine uptake can meaningfully stem the pandemic and offers hope for eventual control of the Sars-CoV-2 outbreak as vaccination programmes ramp up across the rest of the world,\u201d they wrote.<\/span><\/p>\n

Lead author, Dr Sharon Alroy-Preis, of the Israel ministry of health, said: \u201cUntil this point, no country in the world had described the national public health impact of a nationwide Covid-19 vaccination campaign. These insights are hugely important because, while there are still some considerable challenges to overcome, they offer real hope that Covid-19 vaccination will eventually enable us to control the pandemic.\u201d<\/span><\/p>\n

But many other countries will not be able to imitate Israel, commentators in the journal say.<\/span><\/p>\n

article uploaded by: Eva Rozenbaum Yerushalmi<\/strong><\/em><\/span>
\n\"\"\u201cRegrettably, rapid population-level coverage cannot be easily replicated in many other countries. The global use of the [Pfizer\/BioNTech] vaccine is limited by supply issues, high costs, and ultra-cold chain storage requirements,\u201d wrote Prof Eyal Leshem of the Chaim Sheba Medical Centre in Israel, and Prof Annelies Wilder-Smith of the London School of Hygiene & Tropical Medicine, who were not involved in the study.<\/span><\/p>\n

Israel has used only the Pfizer\/BioNTech vaccine, which the company supplied on the understanding that data from the vaccination programme would be published to demonstrate its real-world efficacy.<\/span><\/p>\n

The country had a national lockdown from 27 December 2020 until 7 March 2021 because of a big surge in infections, which peaked in January. By 3 April, 72% of adults over 16 and 90% of the over-65s had received two doses of the vaccine. As in the UK, the dominant strain of the virus has been the \u201cKent\u201d variant, B117. Some cases of the \u201cSouth African\u201d variant, B1351, have been found latterly, but too few to be taken into account.<\/span><\/p>\n

By seven days after the second dose, the vaccine was giving people 95.3% protection against infection and 96\u22197% protection against death. Protection against symptomatic and asymptomatic infection was 97.0% and 91.5%, respectively. Protection against hospital admission was 97.2% overall. By 14 days after the second dose, the protection had risen slightly further.<\/span><\/p>\n

The authors, some of whom declared shares in Pfizer, wrote that \u201crelying on protection against Covid-19 from a single dose might not be prudent\u201d. The vaccine was developed to be given as two shots and substantially higher levels of antibodies have been observed after the second dose.<\/span><\/p>\n

\u201cAdditionally, little is known about the duration of protection of one dose and how it compares with the durability after two doses. It is possible that one dose will provide a shorter duration of protection than two doses, particularly in an environment where new Sars-CoV-2 variants continue to emerge,\u201d they wrote<\/span>.<\/p>\n

In a separate study\u00a0published in the BM<\/strong><\/span>J<\/a>\u00a0on Thursday, researchers from Denmark and Norway revealed their investigations into the blood clots that have been linked to the Oxford\/AstraZeneca vaccine. They looked at 280,000 people aged 18-65 who received a first dose of the vaccine in the two countries in February and March.<\/span><\/p>\n

They found more clots in the veins than would be expected, although the events were still rare \u2013 11 per 100,000 vaccinations. There were 2.5 clots in the veins of the brain per 100,000 jabs.<\/span><\/p>\n

In\u00a0a linked opinion<\/a><\/strong><\/span>, Prof Paul Hunter at the University of East Anglia, said the study did not change the conclusions of the UK and European medicine regulators that the benefits of the Oxford\/AstraZeneca vaccine far outweigh its risks for most age groups.<\/span><\/p>\n

\u201cThose countries that delayed their own vaccination programmes at a time of high transmission rates by declining to use available Oxford\/AstraZeneca vaccines should know that their decision will have contributed to an increase in the number of avoidable deaths from Covid-19,\u201d he writes.<\/span><\/p>\n

\u2026 as it\u2019s our birthday month, we have a small favour to ask. It\u2019s not every day you turn 200. As you\u2019re joining us today from Sweden, we hope you\u2019ll help us celebrate two centuries of independent, high-impact Guardian journalism. Since 1821, tens of millions have placed their trust in our quality reporting, turning to us in moments of crisis, uncertainty, solidarity and hope. And this is just the beginning.<\/span><\/p>\n

Thanks to funding from more than 1.5 million Guardian supporters in 180 countries, we\u2019ve remained open to all, and fiercely independent. With no shareholders or billionaire owner, we set our own agenda and provide truth-seeking journalism that\u2019s free from commercial and political influence. When it\u2019s never mattered more, we can investigate and challenge without fear or favour.<\/span><\/p>\n

Unlike many others, Guardian journalism is available for everyone to read, regardless of what they can afford to pay. We do this because we believe in information equality. Greater numbers of people can keep track of global events, understand their impact on people and communities, and become inspired to take meaningful action.<\/span><\/p>\n

Over the past 200 years, we have reported on the most critical issues and events of the day, and published countless exclusives that have held the powerful to account and exposed incompetence, injustice and impropriety. From Windrush to Wikileaks, Snowden to Cambridge Analytica, and from the climate crisis to racial discrimination, our journalists investigate wrongdoing in the hope that revealing it will help put it right.<\/span><\/p>\n

If there were ever a time to join us, it is now. Every contribution, however big or small, powers our journalism and sustains our future.\u00a0<\/strong><\/span><\/p>\n

\n
\n
\n
\n

Zawarto\u015b\u0107 publikowanych artyku\u0142\u00f3w i materia\u0142\u00f3w nie reprezentuje pogl\u0105d\u00f3w ani opinii Reunion’68,<\/em>
\nani te\u017c webmastera Blogu Reunion’68, chyba ze jest to wyra\u017anie zaznaczone.
\nTwoje uwagi, linki, w\u0142asne artyku\u0142y lub wiadomo\u015bci prze\u015blij na adres:
\n<\/em>webmaster@reunion68.com<\/span><\/a><\/em><\/strong><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n","protected":false},"excerpt":{"rendered":"

Two Pfizer Covid vaccine doses give over 95% protection, shows Israel study Sarah Boseley First research of its kind shows power of vaccines to stem pandemic, cutting hospitalisation, death and infection rates A couple walk past a coronavirus graphic in a vaccination centre in Jerusalem, Israel. Photograph: Debbie Hill\/UPI\/REX\/Shutterstock Two doses of the Pfizer\/BioNTech vaccine […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[6],"tags":[26,24],"_links":{"self":[{"href":"https:\/\/www.reunion68.se\/index.php?rest_route=\/wp\/v2\/posts\/85867"}],"collection":[{"href":"https:\/\/www.reunion68.se\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.reunion68.se\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.reunion68.se\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.reunion68.se\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=85867"}],"version-history":[{"count":9,"href":"https:\/\/www.reunion68.se\/index.php?rest_route=\/wp\/v2\/posts\/85867\/revisions"}],"predecessor-version":[{"id":85878,"href":"https:\/\/www.reunion68.se\/index.php?rest_route=\/wp\/v2\/posts\/85867\/revisions\/85878"}],"wp:attachment":[{"href":"https:\/\/www.reunion68.se\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=85867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.reunion68.se\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=85867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.reunion68.se\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=85867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}